Litigation Details for Alcon Inc. v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)
✉ Email this page to a colleague
Alcon Inc. v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)
| Docket | 1:22-cv-01422 | Date Filed | 2022-10-27 |
| Court | District Court, D. Delaware | Date Terminated | 2025-02-11 |
| Cause | 35:1 Patent Infringement | Assigned To | William C. Bryson |
| Jury Demand | None | Referred To | |
| Parties | PADAGIS US LLC | ||
| Patents | 9,044,484; 9,421,265 | ||
| Attorneys | William G. James | ||
| Firms | Shaw Keller LLP, I.M. Pei Building | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Alcon Inc. v. Padagis Israel Pharmaceuticals Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Alcon Inc. v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-10-27 | External link to document | |||
| 2022-10-27 | 1 | Complaint | expiration of U.S. Patent Nos. 9,044,484 and 9,421,265 (collectively, the “Asserted Patents”). …BACKGROUND 22. U.S. Patent No. 9,044,484 (“the ’484 Patent”), entitled “Aqueous Pharmaceutical… COUNT I: INFRINGEMENT OF U.S. PATENT NO. 9,044,484 35. The Alcon Parties incorporate…claim 1 of the ’484 Patent and at least claim 1 of the ’265 Patent. The Asserted Patents have been listed… COMPLAINT FOR PATENT INFRINGEMENT 1. This is an action for patent infringement by Alcon | External link to document |
| 2022-10-27 | 119 | Notice of Service | Ph.D. Regarding the Invalidity of U.S. Patent Nos. 9,044,484 and 9,421,265 filed by Padagis Israel Pharmaceuticals… 27 October 2022 1:22-cv-01422 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-10-27 | 133 | Notice of Service | Ph.D. Regarding Non-Infringement of U.S. Patent Nos. 9,044,484 and 9,421,265 filed by Padagis Israel Pharmaceuticals… 27 October 2022 1:22-cv-01422 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-10-27 | 136 | Redacted Document | 265 patent is a functional limitation. The same term appears in the 9,044,484 patent (’484 patent) claims…asserted claims of both asserted patents, U.S. Patent Nos. 9,044,484 and 9,421,265. While many asserted… 1-3 and 6-23 of the ’484 patent and claims 1-3 and 6-20 of the ’265 patent. With respect to the first…” in claims 1, 13, and 20 of U.S. Patent 9,142,265 (“the ’265 patent”) should be read as a functional …tactics. Claims 1, 13 and 20 of U.S. Patent 9,142,265 (“the ’265 patent”) – Preservative Limitation First | External link to document |
| 2022-10-27 | 181 | Stipulation-General (See Motion List for Stipulation to Extend Time) | Judgment of Non-Infringement of Claims of U.S. Patent No. 9,421,265 by Alcon Inc., Alcon Laboratories, Inc.,… 27 October 2022 1:22-cv-01422 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
